Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District, Ethiopia

• Published in: Malaria journal 2020-07, Vol.19 (1), p.240-240, Article 240
• Main Authors: Abamecha, Abdulhakim, Yilma, Daniel, Addisu, Wondimagegn, El-Abid, Hassan, Ibenthal, Achim, Noedl, Harald, Yewhalaw, Delenasaw, Moumni, Mohieddine, Abdissa, Alemseged
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antimalarials - therapeutic use; Artemether; Artemether, Lumefantrine Drug Combination - therapeutic use; Artemether-lumefantrine; Asexuality; Blood; Child; Child, Preschool; DNA; Drug dosages; Drug efficacy; Drug resistance; Drug therapy; Drugs; Epidemics; Ethiopia; Female; Fever; Genomes; Genotypes; Genotyping; Health aspects; Hemoglobin; Human diseases; Humans; Infections; Insecticides; Lumefantrine; Malaria; Malaria, Falciparum - prevention & control; Male; Methods; Middle Aged; Mortality; Nucleotide sequence; Parasites; Patient outcomes; PCR; Plasmodium falciparum; Polymerase chain reaction; Prospective Studies; Public health; Survival; Therapeutic efficacy; Uncomplicated malaria; Vector-borne diseases; Young Adult
• ISSN: 1475-2875; 1475-2875
• DOI: 10.1186/s12936-020-03307-4

The efficacy of artemether-lumefantrine (AL) for treatment of uncomplicated Plasmodium falciparum malaria in south-western Ethiopia is poorly documented. Regular monitoring of drug efficacy is an important tool for supporting national treatment policies and practice. This study investigated the therapeutic efficacy of AL for the treatment of P. falciparum malaria in Ethiopia. The study was a one-arm, prospective, evaluation of the clinical and parasitological, responses to directly observed treatment with AL among participants 6 months and older with uncomplicated P. falciparum malaria. Real-time polymerase chain reaction (PCR) and nested PCR reaction methods were used to quantify and genotype P. falciparum. A modified protocol based on the World Health Organization 2009 recommendations for the surveillance of anti-malarial drug efficacy was used for the study with primary outcomes, clinical and parasitological cure rates at day-28. Secondary outcomes assessed included patterns of fever and parasite clearance. Cure rate on day-28 was assessed by intention to treat (ITT) and per protocol (PP) analysis. Parasite genotyping was also performed at baseline and at the time of recurrence of parasitaemia to differentiate between recrudescence and new infection. Of the 80 study participants enrolled, 75 completed the follow-up at day-28 with ACPR. For per protocol (PP) analysis, PCR-uncorrected and-corrected cure rate of AL among the study participants was 94.7% (95% CI 87.1-98.5) and 96% (95% CI 88.8-99.2), respectively. For intention to treat (ITT) analysis, the cure rate was 90% (95% CI 88.8-99.2). Based on Kaplan-Meier survival estimate, the cumulative incidence of failure rate of AL was 3.8% (95% CI 1.3-11.4). Only three participants 3.8% (95% CI 0.8-10.6) of the 80 enrolled participants were found to be positive on day-3. The day three-positive participants were followed up to day 28 and did not correspond to treatment failures observed during follow-up. Only 7.5% (6/80) of the participants were gametocyte-positive on enrollment and gametocytaemia was absent on day-2 following treatment with AL. The therapeutic efficacy of AL is considerably high (above 90%). AL remained highly efficacious in the treatment of uncomplicated malaria in the study area resulted in rapid fever and parasite clearance as well as low gametocyte carriage rates despite the use of this combination for more than 15 years.